| Description |
1 CD-ROM (PDF file (xv, 302 pages, illustrations, charts)) ; 12 cm |
|
4 3/4 in |
| Summary |
Sodium Iodide Symporter (NIS), a therapeutic gene, was studied for the first time in retinoblastoma (RB) correlating the expression with clinicopathological invasiveness of the tumor. The specificity of EpCAM based NIS gene therapy was demonstrated in breast cancer cell as a proof of concept model via 1) EpCAM as tissue specific promoter and 2) nanoformulation, both of which showed encouraging outcomes. In addition, for the first time the upregulated expression of splice variants of survivin, Bax and Bcl-2 in RB tumors was explored indicating their possible role in tumor progression through apoptosis dysregulation. Thus, the above study achieved a profound knowledge about NIS and apoptotic genes in extrathyroidal tumors |
| Notes |
Submitted to the School of Medicine in the Faculty of Health, Deakin University |
|
Thesis (Ph.D.) -- Deakin University, Victoria, 2014 |
| Bibliography |
Bibliography: pages 249-302 |
| Subject |
Cancer -- Treatment.
|
|
Gene therapy.
|
|
Breast -- Cancer.
|
|
Thyroid gland -- Cancer.
|
| Genre/Form |
Academic theses.
|
| Author |
Deakin University. Faculty of Medicine
|
|
Deakin University. School of Health, degree granting institution
|
|
